Evidence map›Paper›PMID 27027999›Full record

ArticleCell cycle (Georgetown, Tex.)2016

MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways.

Alina V Artcibasova, Mikhail B Korzinkin, Maksim I Sorokin, Peter V Shegay, Alex A Zhavoronkov, Nurshat Gaifullin, Boris Y Alekseev, Nikolay V Vorobyev, Denis V Kuzmin, Аndrey D Kaprin and 2 more

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alina V Artcibasovaa Pathway Pharmaceuticals , Wan Chai , Hong Kong, Hong Kong SAR.
Mikhail B Korzinkinc First Oncology Research and Advisory Center , Moscow , Russia.
Maksim I Sorokina Pathway Pharmaceuticals , Wan Chai , Hong Kong, Hong Kong SAR.
Peter V Shegayd P.A. Herzen Moscow Oncological Research Institute , Moscow , Russia.
Alex A Zhavoronkovb Laboratory of Bioinformatics, D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology , Moscow , Russia.
Nurshat Gaifulline Moscow State University, Faculty of Fundamental Medicine , Moscow , Russia.
Boris Y Alekseevd P.A. Herzen Moscow Oncological Research Institute , Moscow , Russia.
Nikolay V Vorobyevd P.A. Herzen Moscow Oncological Research Institute , Moscow , Russia.
Denis V Kuzminf Group for Genomic Regulation of Cell Signaling Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry , Moscow , Russia.
Аndrey D Kaprind P.A. Herzen Moscow Oncological Research Institute , Moscow , Russia.
Nikolay M Borisovg National Research Centre "Kurchatov Institute," Centre for Convergence of Nano-, Bio-, Information and Cognitive Sciences and Technologies , Moscow , Russia.
Anton A Buzdinb Laboratory of Bioinformatics, D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology , Moscow , Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRs) are short noncoding RNA molecules that regulate expression of target mRNAs. Many published sources provide information about miRs and their targets. However, bioinformatic tools elucidating higher level impact of the established total miR profiles, are still largely missing. Recently, we developed a method termed OncoFinder enabling quantification of the activities of intracellular molecular pathways basing on gene expression data. Here we propose a new technique, MiRImpact, which enables to link miR expression data with its estimated outcome on the regulation of molecular pathways, like signaling, metabolic, cytoskeleton rearrangement, and DNA repair pathways. MiRImpact uses OncoFinder rationale for pathway activity calculations, with the major distinctions that (i) it deals with the concentrations of miRs--known regulators of gene products participating in molecular pathways, and (ii) miRs are considered as negative regulators of target molecules, if other is not specified. MiRImpact operates with 2 types of databases: for molecular targets of miRs and for gene products participating in molecular pathways. We applied MiRImpact to compare regulation of human bladder cancer-specific signaling pathways at the levels of mRNA and miR expression. We took 2 most complete alternative databases of experimentally validated miR targets--miRTarBase and DianaTarBase, and an OncoFinder database featuring 2725 gene products and 271 signaling pathways. We showed that the impact of miRs is orthogonal to pathway regulation at the mRNA level, which stresses the importance of studying posttranscriptional regulation of gene expression. We also report characteristic set of miR and mRNA regulation features linked with bladder cancer.

Indexed as

Computational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroRNAsRNA InterferenceSignal TransductionTranscriptomeUrinary Bladder NeoplasmsMicroRNAsbladder cancergene expressionintracellular signaling pathway activationmicro RNAmolecular markersnew bioinformatic methodtotal impact of miR expression

Identifiers

PMID27027999
PMCPMC4845938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.